Studying Genes to Identify Melanoma in Patients in Iceland and Their Family Members

Completed

• Conditions: Melanoma (Skin)

• Registration Number: NCT00346008
• Lead Sponsor: Iceland Genomics Corporation

Brief Summary

RATIONALE: Studying the genes expressed in samples of blood from patients with cancer and their family members may help doctors identify biomarkers related to cancer.

PURPOSE: This clinical trial is studying genes to identify melanoma in patients in Iceland and their family members.

Detailed Description

OBJECTIVES:

* Assess the feasibility of Iceland Genomics Corporation (UVS) to identify melanoma in multiple-case families, individuals with multiple tumors, and selected additional family members in Iceland.

* Assess the feasibility of mutation detection using sequencing and HPLC.

* Determine UVS' ability to create datasets with demographic, epidemiologic and molecular data.

OUTLINE: Participants and patients undergo blood collection and complete lifestyle questionnaires. All patients and population-based controls have DNA samples sequenced for MC1R. Demographic and epidemiologic data on all study participants is collected. Sequencing of the major melanoma susceptibility genes CFDKN2A, CDK4, and MC1R is also performed.

Study Timeline

• Study Start: 2005-10
• Study First Submitted: 2006-06-27
• Study First Submitted QC: 2006-06-27
• Study First Posted: 2006-06-29
• Status Verified: 2008-12
• Primary Completion: 2008-12
• Study Completion: 2009-02
• Last Update Submitted: 2013-05-29
• Last Update Posted: 2013-05-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 2500

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Feasibility to identify melanoma
Feasibility to detect mutation
Ability to create datasets

Trial Locations

Locations (1)

Iceland Genomics Corporation; 🇮🇸 Reykjavik, Iceland